Details

Autor(en) / Beteiligte

• Clement, Fiona M., PhD
• Klarenbach, Scott, MD, MSc
• Tonelli, Marcello, MD, SM
• Wiebe, Natasha, MMath, PStat
• Hemmelgarn, Brenda, MD, PhD
• Manns, Braden J., MD, MSc

Titel

An Economic Evaluation of Erythropoiesis-Stimulating Agents in CKD

Ist Teil von

• American journal of kidney diseases, 2010-12, Vol.56 (6), p.1050-1061

Ort / Verlag

New York, NY: Elsevier Inc

Erscheinungsjahr

2010

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Background The objective was to determine the cost-effectiveness of treating anemic patients with chronic kidney disease (CKD) with erythropoiesis-stimulating agents (ESAs) to a low (9-10.9 g/dL), intermediate (11-12 g/dL), or high (>12 g/dL) hemoglobin level target compared with a strategy of managing anemia without ESAs. Study Design Cost-utility analysis. Setting & Participants Publicly funded health care system. Anemic patients with CKD, overall and stratified into dialysis-/non–dialysis-dependent subgroups. Model, Perspective, & Timeframe Decision analysis, health care payer, patient's lifetime. Main Outcome Cost per quality-adjusted life-year (QALY) gained. Results For dialysis patients, compared with anemia management without ESAs, using ESAs to target a low hemoglobin level is associated with a cost per QALY of $96,270. Given a lack of direct trials comparing low and intermediate targets, significant uncertainty exists between these strategies. Treatment to a high hemoglobin target was always associated with worse clinical outcomes and higher costs compared with a low hemoglobin target. Results were similar in non–dialysis-dependent patients with CKD, with a cost per QALY for a low target compared with no ESA of $147,980. Limitations Given limitations in the available randomized controlled trials, we were able to model only 4 treatment strategies, balancing the need to consider relevant targets with the requirement for accurate estimates of clinical effect. We assumed that the efficacy of the different strategies would continue over a patient's lifetime. Conclusions Using ESAs to target a hemoglobin level >12 g/dL is associated with worse clinical outcomes and significant additional cost compared with using ESAs to target lower hemoglobin levels (9-12 g/dL). Given a lack of studies comparing low (9-10.9 g/dL) and intermediate (11-12 g/dL) hemoglobin targets for clinical outcomes, including quality of life, the most cost-effective hemoglobin level target within the range of 9-12 g/dL is uncertain, although aiming for higher targets within this range will lead to higher costs.